Tuesday, November 26, 2024

Abbott Launches Its TactiFlex Ablation Catheter for Abnormal Heart Rhythm Treatment

Abbott announces the launch of its TactiFlex, Sensor Enabled ablation catheter, the world’s first ablation catheter with a flexible tip and contact force technology. Used for ablation procedures to treat atrial fibrillation (AF), the most common abnormal heart rhythm, the TactiFlex™ catheter can reduce procedure time 1 and improve safety compared to the company’s previous generation catheters 2 .

More than 37 million people worldwide live with atrial fibrillation 3 and the numbers are expected to more than double by 2050 4 . Another five million 5 cases are diagnosed each year, indicating a growing healthcare challenge that demands innovative solutions for patients and their doctors. In Brazil, estimates indicate that up to 5 million people have the disease – without even knowing it. In practice, one in three people hospitalized with cardiac arrhythmia has atrial fibrillation. Among the elderly, the situation is even more critical. On average, 10% of people over 70 years of age have this health problem 6 .

For those who suffer from atrial fibrillation, daily life can be challenging as people often experience dizziness, chest pain, and heart palpitations. Furthermore, it can lead to a stroke if left untreated, which makes it even more critical that it be treated as soon as possible.

“We are entering a new era of ablation procedures for atrial fibrillation due to new technologies developed, such as Abbott’s flexible tip contact force catheter, the TactiFlex. This new catheter along with cutting-edge equipment for mapping arrhythmias cardiac devices, EnSite

Also Read : Shimadzu Medical Systems USA installs first TRINIAS SCORE OPERA Cardiac Catheterization Lab in the US

New catheters and other cutting-edge solutions from Abbott for patients with atrial fibrillation

Unlike other catheters available on the market, TactiFlex™ uses an innovative design with a laser-cut pattern that flexes when in contact with the heart wall. This helps direct fluid to the treated tissue 1 and allows for more precise catheter positioning – providing twice the stability in a beating heart – for consistent therapy delivery 7 .

Abbott, being the company with the most complete portfolio for the treatment of cardiac arrhythmias, has been leading this market with the new technologies developed. The EnSite X Electrophysiology System together with the TactiFlex catheter, allow doctors and patients to feel even more confident that ablation procedures will provide increasingly safe and effective results,” concludes Letícia.

SOURCE : PRNewswire

Subscribe Now

    Hot Topics